Last Price$228.1(1.8%)
Market Cap$16.9B
LTM Free Cash Flow per Share
$3.8
5Y avg
$4.6
Medical - Instruments & Supplies industry
median
$0.0
Stock quality & Intrinsic value
6/10
(0.3%) overvalued
West Pharmaceutical Services, Inc. Free Cash Flow per Share
Annual
Quarterly
LTM
Crunching data... Almost there!
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow per Share | $0.4 | $0.7 | ($0.0) | ($0.1) | $0.4 | $0.9 | $0.5 | $0.8 | $0.9 | $1.0 | $1.1 | $0.7 | $1.8 | $2.4 | $3.2 | $4.0 | $4.4 | $5.9 | $5.6 | $3.8 |
Overvalued or undervalued?
Check the intrinsic value for WST
and see if it's the right time to invest.
West Pharmaceutical Services, Inc. (WST) Free Cash Flow per Share comparison analysis
General
LTM Free Cash Flow per Share
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
West Pharmaceutical Services, Inc.WST
$3.8
(1.9%)
(15.5%)
17.0%
Median Peer Set
$2.9
3.4%
23.0%
10.2%
Becton, Dickinson and CompanyBDX
$10.1
4.2%
18.3%
8.4%
ResMed Inc.RMD
$9.4
10.9%
13.4%
21.8%
AptarGroup, Inc.ATR
$5.3
2.7%
30.2%
10.5%
Hologic, Inc.HOLX
$4.8
(0.0%)
81.1%
19.6%
Intuitive Surgical, Inc.ISRG
$3.0
17.2%
27.7%
27.8%
Masimo CorporationMASI
$2.7
0.6%
(42.5%)
4.0%
Repligen CorporationRGEN
$2.4
(21.1%)
(80.9%)
5.6%
The Cooper Companies, Inc.COO
$1.4
8.4%
32.2%
10.1%
Alcon Inc.ALC
$1.2
8.5%
182.9%
10.3%
Baxter International Inc.BAX
$1.1
(69.5%)
(100.0%)
(6.9%)
WST key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 699.7 29.2% | 913.3 30.5% | 1,020.1 11.7% | 1,051.1 3.0% | 1,055.7 0.4% | 1,104.7 4.6% | 1,192.3 7.9% | 1,266.4 6.2% | 1,368.4 8.1% | 1,421.4 3.9% | 1,399.8 (1.5%) | 1,509.1 7.8% | 1,599.1 6.0% | 1,717.4 7.4% | 1,839.9 7.1% | 2,146.9 16.7% | 2,831.6 31.9% | 2,886.9 2.0% | 2,949.8 2.2% | 2,893.2 (1.9%) |
| Cost of Goods Sold (COGS) | 507.1 | 651.5 | 728.3 | 748.5 | 752.1 | 786.6 | 853.0 | 878.7 | 933.7 | 973.6 | 944.0 | 1,008.0 | 1,086.5 | 1,172.0 | 1,234.2 | 1,379.1 | 1,655.8 | 1,750.7 | 1,820.6 | 1,894.7 |
% margin | 192.6 27.5% | 261.8 28.7% | 291.8 28.6% | 302.6 28.8% | 303.6 28.8% | 318.1 28.8% | 339.3 28.5% | 387.7 30.6% | 434.7 31.8% | 447.8 31.5% | 455.8 32.6% | 501.1 33.2% | 512.6 32.1% | 545.4 31.8% | 605.7 32.9% | 767.8 35.8% | 1,175.8 41.5% | 1,136.2 39.4% | 1,129.2 38.3% | 998.5 34.5% |
| Operating Expenses | 121.7 | 160.8 | 168.6 | 191.9 | 197.6 | 213.3 | 221.7 | 251.3 | 272.8 | 266.0 | 267.1 | 276.6 | 281.7 | 303.2 | 311.6 | 360.9 | 423.5 | 402.2 | 454.0 | 428.6 |
| Research & Development Expenses (R&D) | 0.0 | 0.0 | 16.1 | 18.7 | 19.9 | 23.9 | 29.1 | 33.2 | 37.9 | 37.3 | 34.1 | 36.8 | 39.1 | 40.3 | 38.9 | 46.9 | 52.8 | 58.5 | 68.4 | 69.1 |
| Selling, General & Administrative Expenses (SG&A) | 120.3 | 155.9 | 152.5 | 159.3 | 177.7 | 187.7 | 191.1 | 218.1 | 234.9 | 228.7 | 233.0 | 239.8 | 242.6 | 262.9 | 272.7 | 302.0 | 362.8 | 316.9 | 353.4 | 338.5 |
% margin | 72.2 10.3% | 101.0 11.1% | 94.9 9.3% | 124.1 11.8% | 97.5 9.2% | 90.7 8.2% | 109.6 9.2% | 135.1 10.7% | 162.4 11.9% | 182.0 12.8% | 128.6 9.2% | 196.8 13.0% | 228.9 14.3% | 240.3 14.0% | 296.6 16.1% | 406.9 19.0% | 752.3 26.6% | 734.0 25.4% | 676.0 22.9% | 569.9 19.7% |
| Interest Income | 0.0 | 0.0 | 6.0 | 1.4 | 0.8 | 0.6 | 1.3 | 1.8 | 1.9 | 3.5 | 1.6 | 1.1 | 1.3 | 2.1 | 3.8 | 1.4 | 1.0 | 5.1 | 28.0 | 19.6 |
| Interest Expense | 0.0 | 0.0 | 14.5 | 16.0 | 14.4 | 16.8 | 18.2 | 14.9 | 15.1 | 13.0 | 12.5 | 7.0 | 6.5 | 6.3 | 4.7 | 6.8 | 7.2 | 7.9 | 9.0 | 3.0 |
| Pre-tax Income | 45.2 | 84.5 | 86.4 | 109.5 | 83.1 | 74.5 | 92.7 | 108.6 | 147.1 | 169.0 | 116.1 | 189.8 | 222.4 | 240.7 | 291.8 | 401.3 | 748.9 | 679.9 | 698.0 | 585.5 |
% effective tax rate | (0.4) (0.9%) | 24.6 29.1% | 17.2 19.9% | 23.7 21.6% | 13.5 16.2% | 13.6 18.3% | 23.5 25.4% | 32.7 30.1% | 40.2 27.3% | 47.2 27.9% | 26.3 22.7% | 54.4 28.7% | 80.9 36.4% | 41.4 17.2% | 59.0 20.2% | 72.5 18.1% | 107.2 14.3% | 114.7 16.9% | 122.3 17.5% | 107.5 18.4% |
% margin | 45.6 6.5% | 67.1 7.3% | 70.7 6.9% | 86.0 8.2% | 72.6 6.9% | 65.3 5.9% | 75.5 6.3% | 80.7 6.4% | 112.3 8.2% | 127.1 8.9% | 95.6 6.8% | 143.6 9.5% | 150.7 9.4% | 206.9 12.0% | 241.7 13.1% | 346.2 16.1% | 661.8 23.4% | 585.9 20.3% | 593.4 20.1% | 492.7 17.0% |
| EPS | 0.75 | 1.05 | 1.08 | 1.33 | 1.11 | 0.98 | 1.12 | 1.19 | 1.61 | 1.79 | 1.33 | 1.96 | 2.04 | 2.80 | 3.27 | 4.68 | 8.90 | 7.88 | 7.99 | 6.75 |
| Diluted EPS | 0.71 | 1.00 | 1.02 | 1.25 | 1.06 | 0.95 | 1.08 | 1.15 | 1.57 | 1.75 | 1.30 | 1.91 | 1.99 | 2.74 | 3.21 | 4.57 | 8.67 | 7.73 | 7.88 | 6.69 |
% margin | 122.9 17.6% | 149.9 16.4% | 157.5 15.4% | 186.1 17.7% | 166.4 15.8% | 161.3 14.6% | 183.4 15.4% | 200.0 15.8% | 249.0 18.2% | 273.3 19.2% | 220.0 15.7% | 319.6 21.2% | 335.9 21.0% | 355.3 20.7% | 399.4 21.7% | 531.7 24.8% | 895.2 31.6% | 887.9 30.8% | 844.1 28.6% | 743.9 25.7% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is West Pharmaceutical Services, Inc.'s Free Cash Flow per Share?
As of today, West Pharmaceutical Services, Inc.'s last 12-month Free Cash Flow per Share is $3.8, based on the financial report for Dec 31, 2024 (Q4’2024).
2) What is West Pharmaceutical Services, Inc.'s Free Cash Flow per Share growth rate?
Over the last year, West Pharmaceutical Services, Inc.'s Free Cash Flow per Share growth was (32.0%). The average annual Free Cash Flow per Share growth rates for West Pharmaceutical Services, Inc. have been (0.6%) over the past three years, 3.4% over the past five years.